Inj ceftolozane tazobactam
Products billed under this code include Zerbaxa.
Payment limit per 75mg (50mg cft/25mg taz), by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under this code include Zerbaxa.
Payment limit per 75mg (50mg cft/25mg taz), by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Zerbaxa | Merck Sharp & Dohme LLC | 67919-0030-01 | 200 | $2,003.00 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $10.015 | −$0.023 | 75mg (50mg cft/25mg taz) | Inj ceftolozane tazobactam | v1, posted September 17, 2026 |
| 3Q26 | $10.038 | +$1.202 | 75mg (50mg cft/25mg taz) | Inj ceftolozane tazobactam | v1, posted September 15, 2026 |
| 2Q26 | $8.836 | −$0.111 | 75mg (50mg cft/25mg taz) | Inj ceftolozane tazobactam | v1, posted September 15, 2026 |
| 1Q26 | $8.947 | −$0.119 | 75mg (50mg cft/25mg taz) | Inj ceftolozane tazobactam | v1, posted September 15, 2026 |
| 4Q25 | $9.066 | −$0.062 | 75mg (50mg cft/25mg taz) | Inj ceftolozane tazobactam | v1, posted September 8, 2026 |
| 3Q25 | $9.128 | +$1.087 | 75mg (50mg cft/25mg taz) | Inj ceftolozane tazobactam | v1, posted March 10, 2026 |
| 2Q25 | $8.041 | −$0.108 | 75mg (50mg cft/25mg taz) | Inj ceftolozane tazobactam | v1, posted March 10, 2026 |
| 1Q25 | $8.149 | −$0.081 | 75mg (50mg cft/25mg taz) | Inj ceftolozane tazobactam | v1, posted December 19, 2025 |
| 4Q24 | $8.23 | −$0.011 | 75mg (50mg cft/25mg taz) | Inj ceftolozane tazobactam | v1, posted June 11, 2025 |
| 3Q24 | $8.241 | +$0.952 | 75mg (50mg cft/25mg taz) | Inj ceftolozane tazobactam | v1, posted June 11, 2025 |
| 2Q24 | $7.289 | −$0.081 | 75mg (50mg cft/25mg taz) | Inj ceftolozane tazobactam | v1, posted March 11, 2025 |
| 1Q24 | $7.37 | −$0.111 | 75mg (50mg cft/25mg taz) | Inj ceftolozane tazobactam | v1, posted December 19, 2024 |
| 4Q23 | $7.481 | −$0.059 | 75mg (50mg cft/25mg taz) | Inj ceftolozane tazobactam | v1, posted October 10, 2024 |
| 3Q23 | $7.54 | +$0.826 | 75mg (50mg cft/25mg taz) | Inj ceftolozane tazobactam | v1, posted June 5, 2024 |
| 2Q23 | $6.714 | +$0.158 | 75mg (50mg cft/25mg taz) | Inj ceftolozane tazobactam | v1, posted February 23, 2024 |
| 1Q23 | $6.556 | +$0.205 | 75mg (50mg cft/25mg taz) | Inj ceftolozane tazobactam | v1, posted December 6, 2023 |
| 4Q22 | $6.351 | −$0.044 | 75mg (50mg cft/25mg taz) | Inj ceftolozane tazobactam | v1, posted June 22, 2023 |
| 3Q22 | $6.395 | −$0.003 | 75mg (50mg cft/25mg taz) | Inj ceftolozane tazobactam | v1, posted June 9, 2023 |
| 2Q22 | $6.398 | −$0.239 | 75mg (50mg cft/25mg taz) | Inj ceftolozane tazobactam | v1, posted December 14, 2022 |
| 1Q22 | $6.637 | $0.00 | 75mg (50mg cft/25mg taz) | Inj ceftolozane tazobactam | v1, posted June 8, 2022 |
| 4Q21 | $6.637 | $0.00 | 75mg (50mg cft/25mg taz) | Inj ceftolozane tazobactam | v1, posted June 2, 2022 |
| 3Q21 | $6.637 | +$0.28 | 75mg (50mg cft/25mg taz) | Inj ceftolozane tazobactam | v1, posted June 2, 2022 |
| 2Q21 | $6.357 | −$0.07 | 75mg (50mg cft/25mg taz) | Inj ceftolozane tazobactam | v1, posted March 1, 2022 |
| 1Q21 | $6.427 | – | 75mg (50mg cft/25mg taz) | Inj ceftolozane tazobactam | v1, posted December 10, 2021 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.